Physician profile
John Little
NPI 1649779786
$1,586.96
in general payments reported to CMS, 2019-2025
20 companies · $22.84 in 2025
The $22.84 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $448 · 2023: $703 · 2024: $84.41 · 2025: $22.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.97 | 2022-2023 | |
| Glaxosmithkline, LLC. | $201.23 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $171.70 | 2021-2023 | |
| Pfizer INC. | $161.80 | 2021-2023 | |
| Abbvie INC. | $119.84 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.36 | 2023 | |
| Novo Nordisk INC | $100.12 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $58.40 | 2023 | Otezla, Repatha |
| Qorumpartners | $58.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $56.26 | 2023-2024 | Rexulti |
| Medtronic, INC. | $50.00 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.86 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $45.72 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $42.72 | 2021-2022 | |
| Cochlear Americas | $40.40 | 2024 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.00 | 2021-2022 | |
| Axsome Therapeutics, INC. | $22.18 | 2023 | Sunosi |
| Alkermes, INC. | $21.17 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.77 | 2024 | |
| Dexcom, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.